CHFW - Surrozen and Consonance-HFW Acquisition announce business combination

April, 15 2021 07:49 AM Consonance-HFW Acquisition Corp. Class A

Surrozen, pioneer of targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, and Consonance-HFW Acquisition (CHFW) entered into a definitive business combination agreement.On closure, Consonance-HFW will redomicile as a Delaware corporation and will be renamed Surrozen and its stock is expected to be listed on the Nasdaq under the symbol "SRZN"."We believe that modulation of the Wnt pathway, the body’s own mechanism for tissue repair, has the potential to provide clinical benefit in a broad range of acute and chronic diseases. In 2022, we expect to initiate Phase 1 clinical trials for our lead programs in inflammatory bowel disease and severe alcoholic hepatitis and to advance our ophthalmology programs towards IND," Surrozen's president & CEO Craig Parker commented.Surrozen expects to receive ~$212M in gross proceeds from the business combination, including $120M from a committed PIPE financing and $92M cash in trust from Consonance-HFW.Net proceeds from the business combination will be

For further details see:

Surrozen and Consonance-HFW Acquisition announce business combination

Company Name:	Consonance-HFW Acquisition Corp. Class A
Stock Symbol:	CHFW
Market:	NYSE

Twitter